<p>安尼卡治疗公司（Anika Therapeutics, Inc. ((ANIK)）已举行其第四季度财报电话会议。以下是会议的主要亮点。</p>
<h3>在 TipRanks Premium 上享受 70% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
<p>安尼卡治疗公司最新的财报电话会议描绘了一个谨慎乐观的前景，清晰的商业动能和底线进展与持续的收入压力、监管障碍和 OEM 定价逆风相平衡。管理层强调了第四季度的执行改善、利润率恢复以及通往更强盈利能力的可信路径，尽管他们承认存在重大挑战，这将考验公司在 2026 年及以后的交付能力。</p>
<h2>商业渠道增长</h2>
<p>商业渠道销售是关键亮点，第四季度增长 22%，达到 1330 万美元，全年增长 15%，达到 4840 万美元。管理层将这一增长归功于国际骨关节炎疼痛业务和 Integrity 植入物的加速采用，强调了向更高价值商业收入的战略转变。</p>
<h2>国际 OA 疼痛动能</h2>
<p>国际骨关节炎疼痛收入在第四季度激增 28%，全年增长 12%，Monovisc、Orthovisc 和 Cingal 在多个市场上获得了市场份额。高管们强调了精简的商业和供应链设置，他们相信这可以维持两位数的增长，将这些产品定位为抵消国内 OEM 定价压力的对策。</p>
<h2>Integrity 商业牵引力</h2>
<p>Integrity，安尼卡的肩袖修复解决方案，继续获得动能，2025 年的手术和收入超过翻倍，达到约 600 万美元。自推出以来，已有超过 2500 例手术使用该产品，超过 300 名外科医生现在是活跃用户，仅在第四季度就进行了近 600 例手术，标志着连续第七个季度的环比增长。</p>
<h2>运营和利润改善</h2>
<p>第四季度的运营执行显著改善，GAAP 毛利率从一年前的 56% 扩大至 63%。管理层指出，制造生产力的提升、更高的产出和由于增加的销量带来的运营杠杆，转化为正的运营收入，并为未来的盈利能力提升奠定了基础。</p>
<h2>盈利能力改善（调整后 EBITDA）</h2>
<p>来自持续运营的调整后 EBITDA 在第四季度达到 450 万美元，2025 年为 530 万美元，约占收入的 5%。这一表现超出了公司修订后的预期，后者预计范围从略微负面到适度正面，表明成本控制更加严格，业务组合改善。</p>
<h2>更强的现金生成和资产负债表</h2>
<p>现金生成增强，2025 年的经营现金流上升至 1120 万美元，是去年 540 万美元的两倍多。安尼卡年末现金余额为 5750 万美元，无债务，已资助 680 万美元的资本支出，并执行了 1500 万美元股票回购计划的大部分，突显了资产负债表的灵活性。</p>
<h2>总收入持平和全年下降</h2>
<p>尽管关键领域取得了进展，顶线表现仍然承压，第四季度收入与去年基本持平，为 3060 万美元。全年收入下降 6%，至 1.128 亿美元，符合修订后的指导，但突显出商业渠道的增长尚不足以抵消 OEM 的疲软和其他逆风。</p>
<h2>OEM 渠道逆风和定价压力</h2>
<p>OEM 渠道继续拖累业绩，第四季度收入下降 12%，至 1730 万美元，全年下降 17%，至 6440 万美元。管理层指出，通过与 J&amp;J MedTech 的合作，导致美国骨关节炎疼痛市场的定价下降是主要原因，尽管单位需求和市场领导地位保持不变，但定价压力压缩了收入。</p>
<h2>Hyalofast 临床和监管障碍</h2>
<p>该公司在 Hyalofast 方面遭遇挫折，因为 FastTRACK III 期试验未能达到预先设定的共同主要终点。在 2026 年初，监管机构对涵盖临床和制造数据的 PMA 申请发出了缺陷信，给该项目的前进路径带来了新的不确定性，并增加了监管风险。</p>
<h2>全年毛利率收缩</h2>
<p>尽管第四季度的毛利率趋势令人鼓舞，安尼卡的全年 GAAP 毛利率从 2024 年的 63% 下降至 57%。公司指出，不利的产品组合、早期的制造中断和与遗留项目相关的成本是主要驱动因素，表明持续的毛利率恢复将依赖于持续的销量增长和产品组合的转变。</p>
<h2>Cingal 的监管和时间不确定性</h2>
<p>Cingal 在 2025 年通过了毒性测试，并于 12 月进入生物等效性研究，计划招募不到 60 名患者。然而，管理层强调，潜在的美国监管提交的时间仍不确定，取决于完成招募和生成必要的数据，为长期增长故事增加了另一个变量。</p>
<h2>组织转型和成本措施</h2>
<p>为了支持利润扩张，安尼卡正在实施成本措施，包括领导角色的裁撤和级别变动，预计将带来约 250 万美元的年度人力成本节省和超过 300 万美元的股票薪酬减少。这些举措伴随着高级领导的离职和未填补的 C 级职位，尽管降低了间接费用，但可能会在短期内造成执行风险。</p>
<h2>前瞻性指导和展望</h2>
<p>对于 2026 年，Anika 重申总收入指引为 1.14 亿至 1.225 亿美元，意味着 1% 至 9% 的增长，商业收入目标增长 10% 至 20%，而 OEM 销售预计持平或下降 5%。调整后的 EBITDA 预计将改善至收入的 5% 至 10%，这得益于商业势头、制造效率提升和一般及行政成本削减，同时自由现金流预计大致与去年的运营现金生成持平。</p>
<p>Anika 的财报电话会议传达了一个混合但改善的叙述，强劲的商业吸引力、更好的现金生成和第四季度的利润率恢复被 OEM 定价压力和关键管线资产的监管障碍所抵消。投资者将密切关注管理层是否能够维持商业增长、应对监管障碍，并在未来两年内将初步盈利进展转化为持久的盈利扩张。</p>

阿尼卡医疗

<p>安尼卡医疗（Anika Therapeutics, Inc.）在第四季度的财报电话会议中报告了谨慎乐观的业绩，强调商业渠道销售增长了 22%，达到了 1330 万美元。尽管第四季度的收入持平，为 3060 万美元，全年收入下降了 6%，但运营改善使得 GAAP 毛利率达到了 63%。调整后的息税折旧摊销前利润（EBITDA）在第四季度达到了 450 万美元。然而，OEM 渠道面临挑战，收入下降了 12%。Hyalofast 的监管障碍以及 Cingal 时间表的不确定性增加了公司的挑战，同时削减成本的措施旨在提高盈利能力</p>

<p>Anika Therapeutics, Inc. ((ANIK)) has held its Q4 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>安尼卡治疗公司（Anika Therapeutics, Inc. ((ANIK)）已举行其第四季度财报电话会议。以下是会议的主要亮点。</p>
</div><h3>Claim 70% Off TipRanks Premium</h3>
<div class="lb-trans"><h3>在 TipRanks Premium 上享受 70% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
</div><p>Anika Therapeutics’ latest earnings call painted a cautiously optimistic picture, balancing clear commercial momentum and bottom-line progress against lingering revenue pressure, regulatory setbacks and OEM pricing headwinds. Management stressed improved execution, margin recovery in the fourth quarter and a credible path to stronger profitability, even as they acknowledged material challenges that will test the company’s ability to deliver in 2026 and beyond.</p>
<div class="lb-trans"><p>安尼卡治疗公司最新的财报电话会议描绘了一个谨慎乐观的前景，清晰的商业动能和底线进展与持续的收入压力、监管障碍和 OEM 定价逆风相平衡。管理层强调了第四季度的执行改善、利润率恢复以及通往更强盈利能力的可信路径，尽管他们承认存在重大挑战，这将考验公司在 2026 年及以后的交付能力。</p>
</div><h2>Commercial Channel Growth</h2>
<div class="lb-trans"><h2>商业渠道增长</h2>
</div><p>Commercial channel sales were the key bright spot, climbing 22% in Q4 to $13.3 million and rising 15% for the full year to $48.4 million. Management credited international osteoarthritis pain franchises and accelerating adoption of the Integrity implant as the primary engines of this growth, underscoring a strategic shift toward higher-value commercial revenue.</p>
<div class="lb-trans"><p>商业渠道销售是关键亮点，第四季度增长 22%，达到 1330 万美元，全年增长 15%，达到 4840 万美元。管理层将这一增长归功于国际骨关节炎疼痛业务和 Integrity 植入物的加速采用，强调了向更高价值商业收入的战略转变。</p>
</div><h2>International OA Pain Momentum</h2>
<div class="lb-trans"><h2>国际 OA 疼痛动能</h2>
</div><p>International osteoarthritis pain revenue surged 28% in Q4 and increased 12% for the year, with Monovisc, Orthovisc and Cingal gaining share across several markets. Executives highlighted a lean commercial and supply chain setup that they believe can sustain double-digit growth, positioning these products as a counterweight to domestic OEM pricing pressure.</p>
<div class="lb-trans"><p>国际骨关节炎疼痛收入在第四季度激增 28%，全年增长 12%，Monovisc、Orthovisc 和 Cingal 在多个市场上获得了市场份额。高管们强调了精简的商业和供应链设置，他们相信这可以维持两位数的增长，将这些产品定位为抵消国内 OEM 定价压力的对策。</p>
</div><h2>Integrity Commercial Traction</h2>
<div class="lb-trans"><h2>Integrity 商业牵引力</h2>
</div><p>Integrity, Anika’s rotator cuff repair solution, continued to gain momentum, with procedures and revenue more than doubling in 2025 to roughly $6 million. Since launch, more than 2,500 surgeries have used the product, over 300 surgeons are now active users and nearly 600 procedures were performed in Q4 alone, marking the seventh straight quarter of sequential growth.</p>
<div class="lb-trans"><p>Integrity，安尼卡的肩袖修复解决方案，继续获得动能，2025 年的手术和收入超过翻倍，达到约 600 万美元。自推出以来，已有超过 2500 例手术使用该产品，超过 300 名外科医生现在是活跃用户，仅在第四季度就进行了近 600 例手术，标志着连续第七个季度的环比增长。</p>
</div><h2>Operational and Margin Improvement</h2>
<div class="lb-trans"><h2>运营和利润改善</h2>
</div><p>Operational execution improved notably in the fourth quarter, with GAAP gross margin expanding to 63%, up from 56% a year earlier. Management pointed to better manufacturing productivity, higher throughput and operating leverage from increased volumes, translating into positive operating income and laying a foundation for future profitability gains.</p>
<div class="lb-trans"><p>第四季度的运营执行显著改善，GAAP 毛利率从一年前的 56% 扩大至 63%。管理层指出，制造生产力的提升、更高的产出和由于增加的销量带来的运营杠杆，转化为正的运营收入，并为未来的盈利能力提升奠定了基础。</p>
</div><h2>Improved Profitability (Adjusted EBITDA)</h2>
<div class="lb-trans"><h2>盈利能力改善（调整后 EBITDA）</h2>
</div><p>Adjusted EBITDA from continuing operations reached $4.5 million in Q4 and $5.3 million for 2025, equating to roughly 5% of revenue. This performance topped the company’s revised outlook, which had anticipated a range from slightly negative to modestly positive, signaling tighter cost control and improved business mix.</p>
<div class="lb-trans"><p>来自持续运营的调整后 EBITDA 在第四季度达到 450 万美元，2025 年为 530 万美元，约占收入的 5%。这一表现超出了公司修订后的预期，后者预计范围从略微负面到适度正面，表明成本控制更加严格，业务组合改善。</p>
</div><h2>Stronger Cash Generation and Balance Sheet</h2>
<div class="lb-trans"><h2>更强的现金生成和资产负债表</h2>
</div><p>Cash generation strengthened as operating cash flow rose to $11.2 million in 2025, more than double the prior year’s $5.4 million. Anika ended the year with $57.5 million in cash and no debt, after funding $6.8 million of capital expenditures and executing the bulk of a $15 million share repurchase program, underscoring balance-sheet flexibility.</p>
<div class="lb-trans"><p>现金生成增强，2025 年的经营现金流上升至 1120 万美元，是去年 540 万美元的两倍多。安尼卡年末现金余额为 5750 万美元，无债务，已资助 680 万美元的资本支出，并执行了 1500 万美元股票回购计划的大部分，突显了资产负债表的灵活性。</p>
</div><h2>Total Revenue Flat and Full-Year Decline</h2>
<div class="lb-trans"><h2>总收入持平和全年下降</h2>
</div><p>Despite the progress in key segments, top-line performance remained under pressure, with Q4 revenue essentially flat year over year at $30.6 million. For the full year, revenue declined 6% to $112.8 million, in line with revised guidance but highlighting that growth in the commercial channel was not yet enough to offset OEM weakness and other headwinds.</p>
<div class="lb-trans"><p>尽管关键领域取得了进展，顶线表现仍然承压，第四季度收入与去年基本持平，为 3060 万美元。全年收入下降 6%，至 1.128 亿美元，符合修订后的指导，但突显出商业渠道的增长尚不足以抵消 OEM 的疲软和其他逆风。</p>
</div><h2>OEM Channel Headwinds and Pricing Pressure</h2>
<div class="lb-trans"><h2>OEM 渠道逆风和定价压力</h2>
</div><p>The OEM channel continued to drag results, with revenue down 12% in Q4 to $17.3 million and off 17% for the year at $64.4 million. Management cited lower pricing in the U.S. osteoarthritis pain market through its J&amp;J MedTech partnership as the primary culprit, noting that unit demand and market leadership remained intact but pricing pressure compressed revenue.</p>
<div class="lb-trans"><p>OEM 渠道继续拖累业绩，第四季度收入下降 12%，至 1730 万美元，全年下降 17%，至 6440 万美元。管理层指出，通过与 J&amp;J MedTech 的合作，导致美国骨关节炎疼痛市场的定价下降是主要原因，尽管单位需求和市场领导地位保持不变，但定价压力压缩了收入。</p>
</div><h2>Hyalofast Clinical and Regulatory Setback</h2>
<div class="lb-trans"><h2>Hyalofast 临床和监管障碍</h2>
</div><p>The company faced a setback with Hyalofast as the FastTRACK Phase III trial failed to hit its pre-specified co-primary endpoints. In early 2026, regulators issued a deficiency letter on the PMA filing covering both clinical and manufacturing data, creating fresh uncertainty around the program’s path forward and adding regulatory risk to the pipeline.</p>
<div class="lb-trans"><p>该公司在 Hyalofast 方面遭遇挫折，因为 FastTRACK III 期试验未能达到预先设定的共同主要终点。在 2026 年初，监管机构对涵盖临床和制造数据的 PMA 申请发出了缺陷信，给该项目的前进路径带来了新的不确定性，并增加了监管风险。</p>
</div><h2>Full-Year Gross Margin Contraction</h2>
<div class="lb-trans"><h2>全年毛利率收缩</h2>
</div><p>While Q4 margin trends were encouraging, Anika’s full-year GAAP gross margin slipped to 57% from 63% in 2024. The company pointed to unfavorable product mix, earlier manufacturing disruptions and costs tied to legacy programs as the main drivers, indicating that sustained margin recovery will depend on continued volume growth and portfolio shift.</p>
<div class="lb-trans"><p>尽管第四季度的毛利率趋势令人鼓舞，安尼卡的全年 GAAP 毛利率从 2024 年的 63% 下降至 57%。公司指出，不利的产品组合、早期的制造中断和与遗留项目相关的成本是主要驱动因素，表明持续的毛利率恢复将依赖于持续的销量增长和产品组合的转变。</p>
</div><h2>Regulatory and Timeline Uncertainty for Cingal</h2>
<div class="lb-trans"><h2>Cingal 的监管和时间不确定性</h2>
</div><p>Cingal advanced through toxicity testing in 2025 and entered a bioequivalence study in December, with planned enrollment of just under 60 patients. However, management emphasized that the timing of a potential U.S. regulatory submission remains uncertain and depends on completing enrollment and generating the necessary data, adding another variable to the long-term growth story.</p>
<div class="lb-trans"><p>Cingal 在 2025 年通过了毒性测试，并于 12 月进入生物等效性研究，计划招募不到 60 名患者。然而，管理层强调，潜在的美国监管提交的时间仍不确定，取决于完成招募和生成必要的数据，为长期增长故事增加了另一个变量。</p>
</div><h2>Organizational Transitions and Cost Actions</h2>
<div class="lb-trans"><h2>组织转型和成本措施</h2>
</div><p>To support margin expansion, Anika is implementing cost actions, including leadership role eliminations and leveling changes expected to deliver about $2.5 million in annual headcount savings and more than $3 million in stock-based compensation reduction. These moves come alongside senior leadership departures and unfilled C-suite roles, which could create near-term execution risk even as they lower overhead.</p>
<div class="lb-trans"><p>为了支持利润扩张，安尼卡正在实施成本措施，包括领导角色的裁撤和级别变动，预计将带来约 250 万美元的年度人力成本节省和超过 300 万美元的股票薪酬减少。这些举措伴随着高级领导的离职和未填补的 C 级职位，尽管降低了间接费用，但可能会在短期内造成执行风险。</p>
</div><h2>Forward-Looking Guidance and Outlook</h2>
<div class="lb-trans"><h2>前瞻性指导和展望</h2>
</div><p>For 2026, Anika reiterated total revenue guidance of $114 million to $122.5 million, implying 1% to 9% growth, with commercial revenue targeted to rise 10% to 20% and OEM sales projected to be flat to down 5%. Adjusted EBITDA is expected to improve to 5% to 10% of revenue, supported by commercial momentum, manufacturing gains and general and administrative cost cuts, while free cash flow should roughly match last year’s operating cash generation.</p>
<div class="lb-trans"><p>对于 2026 年，Anika 重申总收入指引为 1.14 亿至 1.225 亿美元，意味着 1% 至 9% 的增长，商业收入目标增长 10% 至 20%，而 OEM 销售预计持平或下降 5%。调整后的 EBITDA 预计将改善至收入的 5% 至 10%，这得益于商业势头、制造效率提升和一般及行政成本削减，同时自由现金流预计大致与去年的运营现金生成持平。</p>
</div><p>Anika’s earnings call delivered a mixed but improving narrative, with strong commercial traction, better cash generation and Q4 margin recovery offset by OEM pricing pressure and regulatory setbacks for key pipeline assets. Investors will be watching closely to see whether management can sustain commercial growth, navigate regulatory hurdles and turn the initial profitability progress into durable earnings expansion over the next two years.</p>
<div class="lb-trans"><p>Anika 的财报电话会议传达了一个混合但改善的叙述，强劲的商业吸引力、更好的现金生成和第四季度的利润率恢复被 OEM 定价压力和关键管线资产的监管障碍所抵消。投资者将密切关注管理层是否能够维持商业增长、应对监管障碍，并在未来两年内将初步盈利进展转化为持久的盈利扩张。</p>
</div>

阿尼卡医疗的财报电话会议显示出谨慎的反弹迹象